Sandoz receives first approval for Airflusal® Forspiro®

Munich, December 18, 2013 – Sandoz announced today that it has received Danish marketing authorization for AirFluSal® Forspiro®, an innovative new inhaler for patients with asthma and/or chronic obstructive pulmonary disease (COPD). The Danish approval follows the completion of EU decentralized procedures (DCP) for eight EU countries, including Denmark.

  • Novel inhaler approved for patients with asthma and COPD
  • Approval follows completion of EU decentralized procedure (DCP)
  • AirFluSal® Forspiro® strengthens Sandoz respiratory portfolio and …
/by